Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has taken bold steps to secure top talent by granting stock options and restricted stock units (RSUs) under its 2024 Inducement Plan. On …
Aclaris Therapeutics Awards Stock Options to Attract Top Talent Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has granted stock options and restricted stock units (RSUs) to multiple new employees, including its recently appointed President and Chief Operating Officer, …
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the highly anticipated Piper Sandler 36th Annual Healthcare Conference. Join the company for a fireside chat featuring key …
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., securing worldwide rights, excluding Greater China, to two promising antibody therapies. This …
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its financial results for the third quarter of 2024, alongside significant corporate updates. The company marked a pivotal milestone with …
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2024 Cantor Global Healthcare Conference, with a management team set to engage in a fireside chat on September …
Aclaris Therapeutics Engages in 2024 Cantor Global Healthcare Conference Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its financial results for the second quarter of 2024 and provided a corporate update. The company reported net revenue of $2.8 …
Aclaris Therapeutics Reports Q2 2024 Financial Results and Updates Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, Interim President and CEO, will join a fireside chat at the Goldman Sachs 45th Annual Global Healthcare …
Aclaris Therapeutics to Participate in Goldman Sachs Healthcare Conference Read More WAYNE, PA — Aclaris Therapeutics (NASDAQ: ACRS), a noted bio-pharmaceutical firm, has made public its financial results for the first quarter of 2024. The announcement was made amidst an outline …
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital-Efficient Immuno-Inflammatory Therapies Read More